Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Rating) person been fixed an mean standing of "Hold" by the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. Three equities probe analysts person rated the banal with a merchantability recommendation, 7 person fixed a clasp proposal and 3 person assigned a bargain proposal to the company. The mean twelve-month terms nonsubjective among analysts that person updated their sum connected the banal successful the past twelvemonth is $15.46.
Several equities analysts person precocious issued reports connected the stock. SVB Leerink dropped their terms people connected shares of Editas Medicine from $14.00 to $7.00 and acceptable a "market perform" standing for the institution successful a probe enactment connected Thursday, November 17th. Credit Suisse Group reaffirmed a "neutral" standing and issued a $13.00 terms nonsubjective connected shares of Editas Medicine successful a probe enactment connected Tuesday, December 6th. Evercore ISI dropped their terms people connected shares of Editas Medicine to $8.00 successful a probe study connected Monday, November 21st. Truist Financial lowered their terms nonsubjective connected shares of Editas Medicine from $80.00 to $35.00 and acceptable a "buy" standing connected the banal successful a probe study connected Friday, November 18th. Finally, Citigroup started sum connected shares of Editas Medicine successful a probe enactment connected Tuesday, December 13th. They acceptable a "neutral" standing and a $11.00 terms nonsubjective for the company.
Institutional Trading of Editas Medicine
Several organization investors and hedge funds person precocious bought and sold shares of EDIT. Continental Investors Services Inc. acquired a caller involvement successful shares of Editas Medicine successful the 3rd 4th worthy $698,000. Bank of New York Mellon Corp raised its presumption successful shares of Editas Medicine by 8.7% during the 3rd quarter. Bank of New York Mellon Corp present owns 253,291 shares of the company's banal valued astatine $3,100,000 aft acquiring an further 20,327 shares during the past quarter. IHT Wealth Management LLC bought a caller involvement successful shares of Editas Medicine during the 3rd 4th valued astatine $165,000. B. Riley Wealth Advisors Inc. acquired a caller presumption successful Editas Medicine successful the 3rd 4th worthy $132,000. Finally, Alpha Paradigm Partners LLC acquired a caller presumption successful shares of Editas Medicine during the 3rd 4th worthy astir $348,000. Institutional investors and hedge funds ain 69.67% of the company's stock.
Editas Medicine Stock Down 1.2 %
Shares of EDIT stock opened astatine $8.87 connected Monday. The steadfast has a marketplace capitalization of $609.93 million, a price-to-earnings ratio of -3.02 and a beta of 1.88. Editas Medicine has a 12-month debased of $8.21 and a 12-month precocious of $28.74. The steadfast has a 50 time moving mean of $10.60 and a 200-day moving mean of $13.14.
Editas Medicine (NASDAQ:EDIT - Get Rating) past released its quarterly net information connected Wednesday, November 2nd. The institution reported ($0.81) net per stock for the quarter, topping the statement estimation of ($0.87) by $0.06. Editas Medicine had a antagonistic nett borderline of 784.32% and a antagonistic instrumentality connected equity of 41.33%. The institution had gross of $0.04 cardinal for the quarter, compared to expert estimates of $5.86 million. Research analysts expect that Editas Medicine volition station -3.21 net per stock for the existent year.
About Editas Medicine
Editas Medicine, Inc, a objective signifier genome editing company, focuses connected processing transformative genomic medicines to dainty a scope of superior diseases. It develops a proprietary cistron editing level based connected CRISPR technology. The institution develops EDIT-101, which is successful Phase 1/2 objective proceedings for Leber Congenital Amaurosis 10 that leads to inherited puerility blindness.
Further Reading
- Get a escaped transcript of the StockNews.com probe study connected Editas Medicine (EDIT)
- MarketBeat: Week successful Review 12/26 – 12/30
- The Dogs Of Tech: It’s Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
This instant quality alert was generated by communicative subject exertion and fiscal information from MarketBeat successful bid to supply readers with the fastest and astir close reporting. This communicative was reviewed by MarketBeat's editorial squad anterior to publication. Please nonstop immoderate questions oregon comments astir this communicative to contact@marketbeat.com.
Should you put $1,000 successful Editas Medicine close now?
Before you see Editas Medicine, you'll privation to perceive this.
MarketBeat keeps way of Wall Street's top-rated and champion performing probe analysts and the stocks they urge to their clients connected a regular basis. MarketBeat has identified the five stocks that apical analysts are softly whispering to their clients to bargain present earlier the broader marketplace catches on... and Editas Medicine wasn't connected the list.
While Editas Medicine presently has a "Hold" standing among analysts, top-rated analysts judge these 5 stocks are amended buys.
English (US)